Facebook
Twitter
LinkedIn
ForwardTitle
Category
Credits
Event date
Cost
- Advanced Practice Provider
- 1.00 Participation
$0.00
Exploration of diet related factors that may affect patient response to anti-cancer immunotherapy.
- Patient Centered Care
- Southeastern American Indian Cancer Health Equity Partnership
- 1.00 Participation
$0.00
Ronny Bell, PhD, MS, and Marc Emerson, PhD, MPH, in this collaborative session will provide context regarding the cancer disparities and efforts to address these disparities for American Indians and Alaska Natives across the US. Dr. Bell will provide context for understanding and addressing cancer disparities among American Indians in North Carolina.
- Advanced Practice Provider
- 1.00 Participation
$0.00
This will be an interactive, introductory session on computed tomography with an emphasis on anatomy and common oncology findings.
- Southeastern American Indian Cancer Health Equity Partnership
- 1.00 Participation
$0.00
Rodney Haring, PhD, MSW, will discuss how treaty and wampum conversations have impacted the cancer care of Indigenous populations. Building on this foundation, Dr. Haring will describe how to create culturally congruent practices that will improve the quality of research and care to benefit Native Nations. Additionally, he will lead attendees in thinking about new ways to work together to provide sustainable cancer care for succeeding generations.
- Research to Practice
- 1.00 Participation
$0.00
Dr. Siddharth Sheth from the UNC Lineberger Head and Neck Oncology group will describe relevant updates in systemic therapy for head and neck cancers for health care providers throughout the state of North Carolina. Additional topical management considerations or recommendations for this patient population may also be presented.
- Research to Practice
- 1.00 Participation
$0.00
This lecture will review some of the new drugs recently FDA approved for management of lymphoma such as CAR-T therapy for relapsed/refractory Mantle Cell Lymphoma or follicular lymphoma. For rel/ref DLBCL, polatuzumab vedotin in combination with bendamustine and rituximab as well as tafasitamab plus lenalidomide have been approved in recent years. We will review the data and outcomes.
- Advanced Practice Provider
- 1.00 Participation
$0.00
Webinar DescriptionBrian Colwell Jensen, MD, will review the potential cardiotoxicity associated with radiation therapy, chemotherapy, and newer targeted cancer therapies.
- Southeastern American Indian Cancer Health Equity Partnership
- 1.00 Participation
$0.00
Webinar DescriptionHannah E. Woriax, MD, will review several case scenarios and patient archetypes that have had their treatment course changed drastically due to recent landmark research studies. Dr. Woriax will then go through a few scenarios relevant to my current patient population specifically. Based on these patient scenarios, she will then discuss potential research possibilities for the future.
- Patient Centered Care
- 1.00 Participation
$0.00
Chemotherapy-induced neuropathy is a major clinical problem that can lead to persistent issues for cancer survivors and can even limit the use of planned chemotherapy treatment during the course of care. Cryotherapy is already an established treatment for other chemotherapy induced conditions such as alopecia and mouth mucositis. This course will explore the evidence for using this low-cost intervention to reduce the incidence/severity of chemotherapy-induced neuropathy.
- Patient Centered Care
- 1.00 Participation
$0.00
Genetic sequencing technologies are increasingly applied in the oncology setting for a variety of purposes. Genetic testing of tumor specimens can help clarify a diagnosis and inform targeted therapies. Kate Foreman, MS, CGC helps us navigate this field.